JP6368722B2 - 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド - Google Patents

網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド Download PDF

Info

Publication number
JP6368722B2
JP6368722B2 JP2015559495A JP2015559495A JP6368722B2 JP 6368722 B2 JP6368722 B2 JP 6368722B2 JP 2015559495 A JP2015559495 A JP 2015559495A JP 2015559495 A JP2015559495 A JP 2015559495A JP 6368722 B2 JP6368722 B2 JP 6368722B2
Authority
JP
Japan
Prior art keywords
peptide
amino acid
glp
retinal
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015559495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510728A (ja
JP2016510728A5 (enExample
Inventor
カノンジュ， ラファエル シモ
カノンジュ， ラファエル シモ
パスクアル， クリスティーナ エルナンデス
パスクアル， クリスティーナ エルナンデス
Original Assignee
フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ
フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ, フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ filed Critical フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ
Publication of JP2016510728A publication Critical patent/JP2016510728A/ja
Publication of JP2016510728A5 publication Critical patent/JP2016510728A5/ja
Application granted granted Critical
Publication of JP6368722B2 publication Critical patent/JP6368722B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015559495A 2013-03-01 2014-02-27 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド Active JP6368722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382063 2013-03-01
EP13382063.9 2013-03-01
PCT/EP2014/053787 WO2014131815A1 (en) 2013-03-01 2014-02-27 Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018029089A Division JP2018111702A (ja) 2013-03-01 2018-02-21 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド

Publications (3)

Publication Number Publication Date
JP2016510728A JP2016510728A (ja) 2016-04-11
JP2016510728A5 JP2016510728A5 (enExample) 2017-03-30
JP6368722B2 true JP6368722B2 (ja) 2018-08-01

Family

ID=47901927

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015559495A Active JP6368722B2 (ja) 2013-03-01 2014-02-27 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
JP2018029089A Pending JP2018111702A (ja) 2013-03-01 2018-02-21 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018029089A Pending JP2018111702A (ja) 2013-03-01 2018-02-21 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド

Country Status (14)

Country Link
US (1) US9707273B2 (enExample)
EP (1) EP2968471B1 (enExample)
JP (2) JP6368722B2 (enExample)
CN (1) CN105007931B (enExample)
CA (1) CA2901439C (enExample)
DK (1) DK2968471T3 (enExample)
ES (1) ES2644016T3 (enExample)
HR (1) HRP20171501T1 (enExample)
HU (1) HUE036542T2 (enExample)
MX (1) MX364911B (enExample)
PL (1) PL2968471T3 (enExample)
PT (1) PT2968471T (enExample)
SI (1) SI2968471T1 (enExample)
WO (1) WO2014131815A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251462B2 (en) 2013-04-23 2019-04-09 Noxell Corporation Hair consultation tool arrangement and method
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US10973867B2 (en) 2015-12-30 2021-04-13 Marshall University Research Corporation Compositions and methods for treating retinopathy
WO2017186934A1 (en) * 2016-04-29 2017-11-02 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
EP3443980A1 (en) * 2017-08-15 2019-02-20 Ciliocure Limited Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies
MX2022009136A (es) * 2020-02-13 2022-08-22 Ferrer Int Composicion farmaceutica oftalmica y uso de la misma.
GB202014740D0 (en) * 2020-09-18 2020-11-04 Invex Therapeutics Ltd Method of reducing intraocular pressure
US20220193201A1 (en) * 2020-10-19 2022-06-23 The Trustees Of The University Of Pennsylvania Glp-1r agonist reduces retinal inflammation and neuron death secondary to ocular hypertension
IL302804A (en) * 2020-11-09 2023-07-01 Tel Hashomer Medical Res Infrastructure & Services Ltd Treatment of ocular diseases
EP4248985A1 (en) 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides for the treatment of retinitis pigmentosa
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
WO2003059373A2 (en) 2002-01-16 2003-07-24 Ramot At Tel Aviv University Ltd. Compositions and their use for enhancing and inhibiting fertilization
US20120021980A1 (en) 2004-08-25 2012-01-26 Aegis Therapeutics, Inc. Compositions for drug administration
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2007062434A2 (en) 2005-11-22 2007-05-31 Crestwave Technologies (Pty) Ltd A mineral recovery process
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
ES2362604B1 (es) 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用

Also Published As

Publication number Publication date
WO2014131815A1 (en) 2014-09-04
EP2968471A1 (en) 2016-01-20
SI2968471T1 (sl) 2017-11-30
HRP20171501T1 (hr) 2017-11-17
CA2901439A1 (en) 2014-09-04
BR112015020143A2 (pt) 2017-08-29
MX364911B (es) 2019-05-13
US20160000882A1 (en) 2016-01-07
PL2968471T3 (pl) 2017-12-29
CN105007931B (zh) 2018-04-06
JP2016510728A (ja) 2016-04-11
US9707273B2 (en) 2017-07-18
PT2968471T (pt) 2017-10-24
JP2018111702A (ja) 2018-07-19
CA2901439C (en) 2023-04-04
HUE036542T2 (hu) 2018-07-30
EP2968471B1 (en) 2017-07-19
CN105007931A (zh) 2015-10-28
DK2968471T3 (en) 2017-10-23
MX2015011243A (es) 2016-04-25
ES2644016T3 (es) 2017-11-27

Similar Documents

Publication Publication Date Title
JP2018111702A (ja) 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
US20210206817A1 (en) Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor
US8889622B2 (en) Methods of inhibiting seizure in a subject
US11918577B2 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
WO2017072498A1 (en) Genetic construct
WO2009121176A1 (en) Insulin-induced gene (insig) peptide compositions and methods for cytoprotection
US20230088633A1 (en) Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
US20190002517A1 (en) Neuropeptide y-derived peptides
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
HK1259373A1 (zh) 用於治疗糖尿病的药物制剂
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina
Do Jai Prakash Rai Extended-release formulations of somatostatin for ocular application and their effect on vascular endothelial growth factor as a biomarker of diabetic retinopathy
CN121729423A (zh) 具有缓解干眼症活性的肽及其用途
Lin The nuclear actions of IGFBP-3
Class et al. Patent application title: NEUROPEPTIDE Y-DERIVED PEPTIDES Inventors: David Paul D. Woldbye (CopenhagenØ, DK) Casper Rene Gøtzsche (Copenhagen Ø, DK) Kristian Klemp (Charlottenlund, DK) Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180709

R150 Certificate of patent or registration of utility model

Ref document number: 6368722

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250